Europe Neurorehabilitation Devices Market Forecast to 2031 - Regional Analysis - by Product Type, Application, and End User

The Europe neurorehabilitation devices market was valued at US$ 631.51 million in 2023 and is expected to reach US$ 1.50 billion by 2031; it is estimated to register a CAGR of 11.5% from 2023 to 2031.

Growing Number of Clinical Studies on Neurorehabilitation Devices Drives Europe Neurorehabilitation Devices Market

Clinical studies validate the safety and effectiveness of newly developed neurorehabilitation devices. They provide evidence that neurorehabilitation devices help improve the quality of life of patients suffering from neurological diseases. These studies encourage healthcare centers to integrate these devices into their treatment programs. For instance, “Clinical Study of a Wearable Remote Rehabilitation Training System for Patients With Stroke: Randomized Controlled Pilot Trial” was published in February 2023. The clinical study aimed to design a remote intelligent rehabilitation training system based on wearable devices and human-computer interaction training tasks and evaluate its safety and efficiency.

In December 2022, a clinical trial study, “Effects of robotic rehabilitation using the Erigo device on patients with neurological injury: a systematic review and meta-analysis of randomized clinical trials,” was published. The trial studied the effects of the Erigo robotic rehabilitation device on patients with neurological injury based on parameters such as safety, muscle strength, spasticity, functionality, gait/balance, and changes in the level of consciousness. The study concluded that Erigo, as a robotic rehabilitation device, is safe for patients with acquired brain injury and can reduce spasticity in patients with stroke.

Thus, the increasing number of clinical studies on neurorehabilitation devices favors the growth of the market worldwide.

Europe Neurorehabilitation Devices Market Overview

The Ruhr- Universitandaumlt Bochum report revealed that about 270,000 people sustain traumatic brain injuries (TBIs) in Germany annually, and it is highly prevalent among those aged 65 years due to gait imbalance. Therefore, the rising frequency of TBI and other neurological conditions has led to the development of innovative products through strategic approaches.

In 2024, Insightec, a pioneer and global leader in focused ultrasound, is pleased to announce that its transcranial MR-guided focused ultrasound (MRgFUS) has been granted NUB status 1 for the treatment of essential tremor (ET) in Germany. This significant milestone is set to improve patient access to cutting-edge, essential tremor treatments within the German healthcare system.

Additionally, the major market players and hospitals are involved in the development of innovative products and therapies for neurorehabilitation. For Instance, neurorehabilitation centers in Germany focused on delivering measurable recoveries by using robotics-based treatments. Advanced robotics and other technologies are effective because they engage the brain differently than traditional methods. They intensify effort and provide data to immediately adapt treatment in real time. TRAINM is one such Nero rehab clinic in Germany providing these services. Thus, above mentioned factors are expected to fuel market growth in the coming years.

Europe Neurorehabilitation Devices Market Revenue and Forecast to 2031 (US$ Million)

Europe Neurorehabilitation Devices Market Segmentation

The Europe neurorehabilitation devices market is categorized into product type, application, end user, and country.

By product type, the Europe neurorehabilitation devices market is segmented into neurorobotic system, brain computer interface, non-invasive stimulators, and wearable devices. The brain computer interface segment held the largest share of the Europe neurorehabilitation devices market share in 2023.

• In terms of application, the Europe neurorehabilitation devices market is segmented into stroke, traumatic brain injury, spinal cord injury, Parkinson's disease, cerebral palsy, and others. The stroke segment held the largest share of the Europe neurorehabilitation devices market share in 2023.
• By end user, the Europe neurorehabilitation devices market is segmented into rehabilitation centers, hospitals & clinics, and home care. The hospitals & clinics segment held the largest share of the Europe neurorehabilitation devices market share in 2023.
• Based on country, the Europe neurorehabilitation devices market is segmented into the UK, Germany, France, Spain, Italy, and the Rest of Europe. Germany segment held the largest share of Europe neurorehabilitation devices Market in 2023.

Abbott Laboratories; BIONIK; BioXtreme Ltd; Blackrock Microsystems Inc; Ekso Bionics Holdings Inc; EMOTIV; Hocoma AG; Medtronic Plc; Renishaw Plc; and Tyromotion GmbH are some of the leading companies operating in the Europe neurorehabilitation devices market.

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe neurorehabilitation devices market.
• Highlights key business priorities to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the Europe neurorehabilitation devices market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe neurorehabilitation devices market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.